Insights Into Chronic Lymphocytic Leukemia (CLL)
Perspectives of community physicians on the treatment of CLL
Faculty Chair
Mazyar Shadman, MD
Fred Hutchinson Cancer Center, Seattle, WA, USA
Faculty Chair
Ryan Jacobs, MD
Atrium Health, Charlotte, NC, USA
Faculty Chair
Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX, USA
Faculty Chair
John Allan, MD
Weill Cornell Medicine, New York, NY, USA
Faculty Chair
Nitin Jain, MD
MD Anderson Cancer Center, Houston, TX, USA
Faculty Chair
John Allan, MD
Weill Cornell Medicine, New York, NY, USA
Faculty Chair
Matthew Davids, MD
Dana-Farber Cancer Institute, Boston, MA, USA
Faculty Chair
Matthew Davids, MD
Dana-Farber Cancer Institute, Boston, MA, USA
Faculty Chair
Brad Kahl, MD
Washington University, St. Louis, MO, USA
Faculty Chair
Brad Kahl, MD
Washington University, St. Louis, MO, USA
More Information
- Virtual series
- Southern California, Nevada, Utah, Arizona, New Mexico, Colorado
More Information
- Atlanta, GA
- Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia
More Information
- Dallas, TX
- Kansas, Oklahoma, Texas, Missouri, Arkansas, Louisiana
More Information
- Virtual Series
- Kansas, Oklahoma, Texas, Missouri, Arkansas, Louisiana
More Information
- Dallas, TX
- Kansas, Oklahoma, Texas, Missouri, Arkansas, Louisiana
More Information
- Virtual Series
- New York, Florida, Atlanta, New Jersey, Virginia
More Information
- Virtual Series
- New York, Texas, Illinois, Indiana, New Jersey, Pennsylvania
More Information
- Virtual Series
- California, Arizona, Wyoming, Washington
More Information
- Chicago, IL
- Illinois, Iowa, Minnesota, Nebraska, North Dakota, South Dakota, Wisconsin, Michigan, Indiana, Ohio
More Information
- Baltimore, MD
- Connecticut, Delaware, District of Columbia, Maine, Massachusetts, Maryland, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont
More Information
- Seattle, WA
- Northern California, Oregon, Washington, Idaho, Montana, Wyoming
REPORT SNAPSHOT
- A moderated roundtable discussion focusing on the treatment of CLL
- Disease state and data presentations are developed in conjunction with a national or regional oncology expert
- Insights on the following therapies will be obtained: acalabrutinib, ibrutinib, zanubrutinib, obinutuzumab, rituximab, venetoclax, duvelisib, idelalisib, FCR, and BR
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection is accomplished through use of audience response system questioning and moderated discussion
- The group of advisors comprises 10–15 medical oncologists representative of each region
